Crossmark

Confirmation of p-tau Ser356’s association with Alzheimer’s disease pathology and lowering in response to WZ4003 treatment in brain slice cultures. Reply to: “Phospho-tau Ser356 is mostly confined to pre-NFT neurons in Alzheimer’s pathology”

Crossref DOI link: https://doi.org/10.1007/s00401-025-02966-4

Published Online: 2025-12-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Taylor, Lewis W. https://orcid.org/0009-0006-6014-3734
Simzer, Elizabeth M. https://orcid.org/0000-0002-7043-1450
Young, Lauren F. P. https://orcid.org/0009-0002-1612-1555
Holt, Kristján https://orcid.org/0000-0003-3903-6361
Spires-Jones, Tara L. https://orcid.org/0000-0003-2530-0598
Durrant, Claire S. https://orcid.org/0000-0001-7552-7358
Funding

Funding for this research was provided by:

UK Dementia Research Institute (UKDRI-Edin005)

Race Against Dementia (RADF-2019a-001)

James Dyson Foundation

Alzheimer's Society (AS-PG-21-006)
License Information

Text and Data Mining valid from 2025-12-11

Version of Record valid from 2025-12-11
More Information

Article History

Received: 19 November 2025

Revised: 24 November 2025

Accepted: 25 November 2025

First Online: 11 December 2025

Declarations

:

: Claire Durrant has no direct conflicts of interest with this study but receives funding from ONO Pharmaceuticals for a separate project. Tara Spires-Jones has no direct conflicts of interest with this study but has received payments for consulting, scientific talks, or collaborative research over the past 10 years from AbbVie, Sanofi, Merck, Scottish Brain Sciences, Jay Therapeutics, Cognition Therapeutics, ONO Pharmaceuticals, and Eisai. She is also a charity trustee for the British Neuroscience Association and the Guarantors of Brain and serves as a scientific advisor to several charities and non-profit institutions. The remaining authors declare no competing interests.

Document is current

Any future updates will be listed below